HK Stock Market Move | CF PHARMTECH (02652) rose by more than 5% "drug+device" to meet strategic synergy Self-developed EBV successfully discharged the first severe emphysema patient from clinical group.

CF PHARMTECH (02652) rose more than 5%, up 3.34% as of the time of writing, to 21.64 Hong Kong dollars, with a trading volume of 10.74 million Hong Kong dollars. On the news front, on April 27th, CF PHARMTECH announced a key clinical advancement in the field of respiratory intervention medical device treatment: its self-developed endobronchial valve (EBV) showed promising treatment results in the clinical trial for severe emphysema, with the first patient showing good post-operative treatment effects and successfully completing clinical observation and discharge from the trial. This development signifies the company's achievement of a systematic pipeline layout from inhaled drugs to intervention devices. The successful completion and discharge of the first patient in the clinical trial marks an important milestone in the development process of the EBV project and accumulates valuable experience for the subsequent clinical trials. As a comprehensive innovative pharmaceutical company that focuses on the research, development, production, and commercialization of inhaled pharmaceuticals and respiratory system diseases, CF PHARMTECH has established a product matrix covering multiple diseases such as asthma, COPD, and allergic rhinitis. The company possesses five core technology platforms including particle engineering, device design, product performance evaluation, clinical development, and process engineering, supporting the simultaneous research and development of innovative drugs and devices. The steady progress of the EBV project enables the company to extend its treatment from inhaled drugs to intervention devices, creating a comprehensive disease management plan covering mild to moderate drug interventions to severe diseases requiring device interventions, further strengthening its comprehensive layout in the field of respiratory disease treatment.